Multiple myeloma and autologous haematopoietic stem-cell transplantation without cryopreservation: experiences of the Clinical Hematology Department of Casablanca, Morocco

被引:0
作者
Fares, Salma [1 ]
Hadri, Halima [1 ]
Rachid, Mohamed [1 ]
Moutiqui, Tarik [1 ]
Oukkache, Bouchra [2 ]
Quessar, Asmaa [1 ]
机构
[1] CHU Ibn Rochd, Hop 20 Aout 1953, Serv Hematol & Oncol Pediat, Casablanca, Morocco
[2] CHU Ibn Rochd, Serv Hematobiol, Casablanca, Morocco
关键词
Multiple myeloma; autologous haematopoietic stem-cell transplantation; without cryopreservation; HIGH-DOSE CHEMOTHERAPY; SINGLE-CENTER EXPERIENCE; INSTITUTION; SURVIVAL; THERAPY;
D O I
10.11604/pamj.2021.39.105.18994
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) is the gold standard treatment for multiple myeloma in subjects aged <= 65 years. In developing countries, AHSCT without cryopreservation reduces the costs of hospitalization and all necessary equipments. We conducted a longitudinal, prospective, open study to evaluate this procedure at the Department of Clinical Hematology, Casablanca, Morocco. Data from the medical records of 64 patients were collected over a period of 24 months. After induction therapy, the overall response (complete remission + very good partial response) was 67.2% (43 patients). The mean CD34-cell count in the autograft was 12.97*10(6) /kg [2.4- 53*10(6) Cd34+/kg] and the median length of hospitalization was 20.5 days [14-60 days]. The overall response after autograf was 84% (54 patients). At 24 months follow-up, overall survival (OS) was 83.5%, median DS was not reached and progression free survival (PFS) was 65.9%, with a median PFS of 24.1 months with 95% confidence interval [21.7-26.5 months]. Autologous hematopoietic stem cell transplantation without cryopreservation is an excellent alternative in our context reducing wait times and freezing costs.
引用
收藏
页数:12
相关论文
共 20 条
[1]  
Altekruse S F., SEER CANC STAT REV 1
[2]  
Bekadja M-A, 2012, Hematol Oncol Stem Cell Ther, V5, P49, DOI 10.5144/1658-3876.2012.49
[3]   International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation [J].
Cavo, Michele ;
Rajkumar, S. Vincent ;
Palumbo, Antonio ;
Moreau, Philippe ;
Orlowski, Robert ;
Blade, Joan ;
Sezer, Orhan ;
Ludwig, Heinz ;
Dimopoulos, Meletios A. ;
Attal, Michel ;
Sonneveld, Pieter ;
Boccadoro, Mario ;
Anderson, Kenneth C. ;
Richardson, Paul G. ;
Bensinger, William ;
Johnsen, Hans E. ;
Kroeger, Nicolaus ;
Gahrton, Gosta ;
Bergsagel, P. Leif ;
Vesole, David H. ;
Einsele, Hermann ;
Jagannath, Sundar ;
Niesvizky, Ruben ;
Durie, Brian G. M. ;
San Miguel, Jesus ;
Lonial, Sagar .
BLOOD, 2011, 117 (23) :6063-6073
[4]   Hematologic reconstitution following high-dose and supralethal chemoradiotherapy using stored, noncryopreserved autologous hematopoietic stem cells [J].
Cuellar-Ambrosi, F ;
Karduss, UA ;
Gómez, WR ;
Mondragón, MC ;
Velasquez-Lopera, M ;
Calle, S .
TRANSPLANTATION PROCEEDINGS, 2004, 36 (06) :1704-1705
[5]   High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial [J].
Fermand, JP ;
Ravaud, P ;
Chevret, S ;
Divine, M ;
Leblond, V ;
Belanger, C ;
Macro, M ;
Pertuiset, E ;
Dreyfus, F ;
Mariette, X ;
Boccacio, C ;
Brouet, JC .
BLOOD, 1998, 92 (09) :3131-3136
[6]   International staging system for multiple myeloma [J].
Greipp, PR ;
San Miguel, J ;
Durie, BGM ;
Crowley, JJ ;
Barlogie, B ;
Bladé, J ;
Boccadoro, M ;
Child, JA ;
Harousseau, JL ;
Kyle, RA ;
Lahuerta, JJ ;
Ludwig, H ;
Morgan, G ;
Powles, R ;
Shimizu, K ;
Shustik, C ;
Sonneveld, P ;
Tosi, P ;
Turesson, I ;
Westin, J .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420
[7]   Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials [J].
Harousseau, Jean-Luc ;
Avet-Loiseau, Herve ;
Attal, Michel ;
Charbonnel, Catherine ;
Garban, Frederic ;
Hulin, Cyrille ;
Michallet, Mauricette ;
Facon, Thierry ;
Garderet, Laurent ;
Marit, Gerald ;
Ketterer, Nicolas ;
Lamy, Thierry ;
Voillat, Laurent ;
Guilhot, Francois ;
Doyen, Chantal ;
Mathiot, Claire ;
Moreau, Philippe .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5720-5726
[8]   High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: A Single Institution Experience at All India Institute of Medical Sciences, New Delhi, Using Non-Cryopreserved Peripheral Blood Stem Cells [J].
Kayal, Smita ;
Sharma, Atul ;
Iqbal, Sobuhi ;
Tejomurtula, Tilak ;
Cyriac, Sunu L. ;
Raina, Vinod .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (02) :140-147
[9]   High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials [J].
Koreth, John ;
Cutler, Corey S. ;
Djulbegovic, Benjamin ;
Behl, Rajesh ;
Schlossman, Robert L. ;
Munshi, Nikhil C. ;
Richardson, Paul G. ;
Anderson, Kenneth C. ;
Soiffer, Robert J. ;
Alyea, Edwin P., III .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) :183-196
[10]   Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients [J].
Krejci, M ;
Buchler, T ;
Hajek, R ;
Svobodnik, A ;
Krivanova, A ;
Pour, L ;
Adam, Z ;
Mayer, J ;
Vorlicek, J .
BONE MARROW TRANSPLANTATION, 2005, 35 (02) :159-164